Brief: Trevi Therapeutics Announces Positive Data From Full Set Of Subjects In Phase 2 Canal Trial Of Haduvio

Trevi Therapeutics

19/09/2022 12:54

Sept 19 (Reuters) - Trevi Therapeutics Inc  TRVI.O :
    * TREVI THERAPEUTICS ANNOUNCES POSITIVE DATA FROM FULL SET
OF
SUBJECTS IN PHASE 2 CANAL TRIAL OF HADUVIO™ IN THE TREATMENT OF
CHRONIC COUGH IN IDIOPATHIC PULMONARY FIBROSIS
    * TREVI THERAPEUTICS ANNOUNCES POSITIVE DATA FROM FULL SET
OF
SUBJECTS IN PHASE 2 CANAL TRIAL OF HADUVIO™ IN THE TREATMENT OF
CHRONIC COUGH IN IDIOPATHIC PULMONARY FIBROSIS
    * TREVI THERAPEUTICS INC - DATA FROM FULL SET OF SUBJECTS
WAS
STATISTICALLY SIGNIFICANT FOR PRIMARY EFFICACY ENDPOINT OF
DAYTIME COUGH FREQUENCY REDUCTION
    * TREVI THERAPEUTICS INC - MAGNITUDE OF DAYTIME AND 24HR
COUGH
FREQUENCY REDUCTION WERE CONSISTENT
    * TREVI THERAPEUTICS INC - KEY SECONDARY ENDPOINTS ON
PATIENT AND
CLINICIAN REPORTED OUTCOMES WERE ALSO STATISTICALLY SIGNIFICANT

Source text for Eikon:  ID:nPn3YJb3Ta 
Further company coverage:  TRVI.O 

 ((Reuters.Briefs@thomsonreuters.com;))